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Abstract: Microbial resistance to currently available antibiotics is a public health problem in the
fight against infectious diseases. Most antibiotics are characterized by numerous side effects that
may be harmful to normal body cells. To improve the efficacy of these antibiotics and to find an
alternative way to minimize the adverse effects associated with most conventional antibiotics, piperine
and piperlongumine were screened in combination with conventional rifampicin, tetracycline, and
itraconazole to evaluate their synergistic, additive, or antagonistic interactions against Staphylococcus
aureus, Pseudomonas aeruginosa, and Candida albicans. The fractional inhibitory concentration index
was used to estimate the synergistic effects of various combination ratios of the piperamides and
antibiotics against the bacterial and fungal strains. Both piperine and piperlongumine showed
synergistic effects against S. aureus when combined at various ratios with rifampicin. Synergistic
interaction was also observed with piperine in combination with tetracycline against S. aureus, while
antagonistic interaction was recorded for piperlongumine and tetracycline against S. aureus. All the
piperamide/antibacterial combinations tested against P. aeruginosa showed antagonistic effects, with
the exception of piperine and rifampicin, which recorded synergistic interaction at a ratio of 9:1
rifampicin/piperine. No synergistic interaction was observed when the commercial compounds were
combined with itraconazole and tested against C. albicans. The results showed that piperine and
piperlongumine are capable of improving the effectiveness of rifampicin and tetracycline. Dosage
combinations of these bioactive compounds with the antibiotics used may be a better option for the
treatment of bacterial infections that aims to minimize the adverse effects associated with the use of
these conventional antibacterial drugs.
Keywords: piperine; piperlongumine; antibacterial; antifungal; synergy
1. Introduction
Infectious diseases caused by bacteria and fungi are one of the leading causes of death
worldwide [1–3]. The emergence of multidrug resistance in microbes and the nonavailability of
antibiotics to combat and treat microbial infections have led to a constant search for new antimicrobial
agents from natural sources. Previous research has shown that about 13 million deaths are recorded
throughout the world each year as a result of bacterial and fungal diseases that are often caused by
multidrug-resistant pathogens [4,5]. Natural products of plant origin include novel therapeutic and
highly effective antimicrobial agents [6,7]. In clinical practice, one of the leading new advances in the
fight against microbial resistance is antimicrobial combination therapy [8–10]. Alternatively, bioactive
compounds from natural sources could also be screened for leads to the discovery of new antibiotics
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to combat microbial resistance [5,11,12]. The mode of activity of antimicrobial combination therapy
in antimicrobial treatments differs from that of the same individual antibiotics when administered
as single drugs [8,13]. Bioactive compounds and extracts from plants can also potentiate the effect of
antimicrobial drugs, thereby acting as antibiotic adjuvants [5,11]. Another strategic approach to the
fight against multidrug-resistant bacteria in clinical practice is to deactivate the resistance mechanism
of the bacteria to the existing antibiotics. In addition, pharmacological studies have shown that
synergistic interaction is necessary and could greatly enhance the activity of antimicrobial compounds
with moderate or weak activity. Thus, these bioactive plant compounds can serve as inhibitors against
multidrug-resistant pathogens [5,14].
Piperine (1) and piperlongumine (2) are novel alkaloids found in most Piper species.
Piperlongumine (2), also known as piplartin, is a piperamide compound found in Indian long
pepper Piper longum L. [15]. It is a bioactive compound of clinical importance that is active against
multidrug-resistant pathogens such as Pseudomonas aeruginosa (Schroeter) Mogul and Staphylococcus
aureus Rosenbach [16]. Piperine (1) is a piperamide compound found in Piper guineense Schumach.
& Thonn., black pepper Piper nigrum L., and other Piper species [17–19]. The chemical structures
of piperine and piperlongumine are shown in Figure 1. Previous research has shown that piperine
is a potent antibacterial agent acting as an inhibitor of the efflux pump of S. aureus [20,21]. Recent
pharmacological research on piperine and piperlongumine [22–25] led us to hypothesize that these
piperamide compounds may potentiate the antibiotic effect of some conventional antimicrobials,
thereby acting as antibiotic adjuvants.
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2. Results
To evaluate an alternative way to fight multidrug-resistant pathogens and to minimize the adverse
effects associated with most conventional antibiotics, piperine and piperlongumine were screened
singly and in combination with conventional antimicrobials to determine their synergistic, additive,
or antagonistic interactions against S. aureus, P. aeruginosa, and C. albicans (Table 1, Figures 2 and 3).
The aim was to investigate the synergistic effects of piperine and piperlongumine when used singly
and in combination with conventional antimicrobials against S. aureus, P. aeruginosa, and C. albicans.
S. aureus, P. aeruginosa, and C. albicans are pathogens that are capable of causing systemic infections
in humans. As such, 90–95% of S. aureus strains are resistant to most conventional antibiotics [8,26].
The fractional inhibitory concentration (FIC) index was used to determine the synergistic interaction
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between the commercial piperamides and the antimicrobials. The FIC index method is one of the most
accurate means for determining synergistic interactions when two inhibitors are studied in various
combinations [27,28]. A synergistic effect was observed when the FIC index value of the compound of
interest was ≤ 0.5 [26]. Previous research has also shown that the ratio of combination of two inhibitors
could influence the degree of their interaction, such that the interactions could vary depending on the
ratio by which the two inhibitors are combined [28].
Table 1. Inhibition zone diameters (mm) of the antibacterial and antifungal effects of piperine,
piperlongumine (P. longumine), rifampicin, tetracycline, itraconazole, and 70% ethanol tested
individually against Staphylococcus aureus, Pseudomonas aeruginosa, and Candida albicans, using the agar
diffusion method.
Bacteria/Fungi Piperine P. longumine Tetracycline Rifampicin 70% Ethanol Itraconazole
S. aureus 15.2 ± 0.31 12.4 ± 0.31 49.1 ± 0.32 47.2 ± 0.17 NA NP *
P. aeruginosa 14.4 ± 0.33 11.5 ± 0.33 34.6 ± 0.33 30.3 ± 0.33 NA NP *
C. albicans 16.5 ± 0.31 18.2 ± 0.31 NP * NP * NA 15.2 ± 0.33
NA, not active; *, not performed. The inhibition zone diameters (mm) represent the means of three replicates (n = 3)
± the SEM (standard error of the mean).
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Figure 2. Inhibition zone dia eters ( ) of the antibacterial and antifungal effects of piperine and
i erlong ine combined at various ratios with rifampicin/itraconazole against S. aureus, P. aeruginosa,
and C. albicans, using the agar diffusion method. Rif, rifampicin; Itr, itraconazole; piper, piperine; p.long,
i rlongumi e; 200 µL f the pip ramide/antimicrobial combinations were applied in the wells.
The results of the first preliminary agar diffusion method performed singly on the piperamide
compounds and antibacterials against S. aureus showed that the inhibition zone diameters of
tetracycline, rifampicin, piperine, and piperlongumine were 49.1 mm, 47.2 mm, 15.2 mm, and
12.4 mm, respectively (Table 1). Preliminary agar diffusion screening was also performed on the
various piperamide/antimicrobial combinations to ascertain the five best combinations to screen for the
minimum inhibitory concentrations (MICs) and FIC index calculations for synergistic or antagonistic
evaluations (Figures 2 and 3).
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Table 2. Cont.
Ratioof Antibiotics/Compound S. aureus P. aeruginosa C. albicans
Itracon + piperine 1:9 NP * NP * 3.9
Itracon + piperine 3:7 NP * NP * 3.9
Itracon + piperine 5:5 NP * NP * 7.8
Itracon + piperine 7:3 NP * NP * 7.8
Itracon + piperine 9:1 NP * NP * 15.6
Itracon + piperlongumine 1:9 NP * NP * 31.2
Itracon + piperlongumine 3:7 NP * NP * 7.8
Itracon + piperlongumine 5:5 NP * NP * 7.8
Itracon + piperlongumine 7:3 NP * NP * 3.9
Itracon + piperlongumine 9:1 NP * NP * 31.2
Piperine only 3.9 15.6 7.8
Piperlongumine only 15.6 31.2 3.9
Rifampicin only 1.97 0.48 NP *
Tetracycline only 0.97 0.97 NP *
Itraconazole only NP * NP * 15.6
The MIC values represent the means of triplicates. Only five combinations were tested for MIC. *, not performed.
Rifampicin and tetracycline were combined at various ratios with piperine and piperlongumine
and tested against S. aureus. For piperlongumine, a synergistic effect was observed at a ratio of 5:5
with rifampicin against this bacterium (Table 3). This result demonstrates that the pharmacological
interaction between a bioactive compound and a conventional antimicrobial can be affected by the ratio
and concentration at which the two are combined. However, antagonistic interactions were observed
between piperlongumine and tetracycline at all the combination ratios tested against this bacterium
(Table 3).
Table 3. Antimicrobial synergistic activity of piperine and piperlongumine against S.aureus, P. aeruginosa,
and C. albicans.
Ratio
FIC Index
S. aureus P. aeruginosa C. albicans
Rifam + piperine 1:9 5.9 (AT) 33.5 (AT) NP *
Rifam + piperine 3:7 0.2 (S) 33.5 (AT) NP *
Rifam + piperine 5:5 3.9 (AT) 8.0 (AT) NP *
Rifam + piperine 7:3 1.2 (I) 5.0 (AT) NP *
Rifam + piperine 9:1 12.6 (AT) 0.4 (S) NP *
Rifam + piperlongumine 1:9 4.4 (AT) 66.0 (AT) NP *
Rifam + piperlongumine 3:7 39.0 (AT) 33.0 (AT) NP *
Rifam + piperlongumine 5:5 0,5 (S) 1.5 (I) NP *
Rifam + piperlongumine 7:3 17.0 (AT) 2.0 (I) NP *
Rifam + piperlongumine 9:1 17.0 (AT) 1.0 (I) NP *
Tetracy + piperine 1:9 10.0 (AT) 68.0 (AT) NP *
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Table 3. Cont.
Ratio
FIC Index
S. aureus P. aeruginosa C. albicans
Tetracy + piperine 3:7 4.5 (AT) 32.0 (AT) NP *
Tetracy + piperine 5:5 0.3 (S) 0.7 (A) NP *
Tetracy + piperine 7:3 2.4 (AT) 0.7 (A) NP *
Tetracy + piperine 9:1 12.1 (AT) 1.5 (I) NP *
Tetracy + piperlongumine 1:9 34.1 (AT) 33.1 (AT) NP *
Tetracy + piperlongumine 3:7 4.1 (AT) 8.2 (AT) NP *
Tetracy + piperlongumine 5:5 1.1 (I) 2.5 (AT) NP *
Tetracy + piperlongumine 7:3 0.9 (A) 1.5 (I) NP *
Tetracy + piperlongumine 9:1 48.9 (AT) 1.5 (I) NP *
Itracon + piperine 1:9 NP * NP * 0.8 (A)
Itracon + piperine 3:7 NP * NP * 1.2 (I)
Itracon + piperine 5:5 NP * NP * 4.0 (AT)
Itracon + piperine 7:3 NP * NP * 3.0 (AT)
Itracon + piperine 9:1 NP * NP * 4.0 (AT)
Itracon + piperlongumine 1:9 NP * NP * 10.1 (AT)
Itracon + piperlongumine 3:7 NP * NP * 0.7 (A)
Itracon + piperlongumine 5:5 NP * NP * 1.3 (I)
Itracon + piperlongumine 7:3 NP * NP * 1.0 (I)
Itracon + piperlongumine 9:1 NP * NP * 12.0 (AT)
The activity is expressed as the fractional inhibition concentration (FIC) index, which is calculated from the MIC
of the various piperamide/antimicrobial combinations. The FIC index interactions were defined as: FICI ≤ 0.5,
(S) synergy; >0.5 to ≤1.0, (A) additive; >1.0 to ≤2.0, (I) indifferent; and >2.0, (AT) antagonistic [26]. *, not performed.
3. Discussion
3.1. Antibacterial Synergistic Effects of Piperine and Piperlongumine against S. aureus
For piperine, the FIC index value of rifampicin and piperine against S. aureus in this study
showed synergistic interaction at a ratio of 3:7 (Table 3). A synergistic effect was observed between
piperine and rifampicin and between piperine and tetracycline, as shown in Table 3. Rifampicin
is an antibiotic that is often used in the treatment of systemic bacterial infections in antimicrobial
therapy, and this antibiotic is characterized by numerous adverse effects when used consecutively for
10–14 days [29,30]. A formulation containing a fixed-dose combination of rifampicin and piperine
(rifampicin 200 mg + piperine 10 mg) has been approved in India to minimize the adverse effects
associated with the use of conventional rifampicin in the antimicrobial treatment against Mycobacterium
tuberculosis [30]. Our results show here that piperine could be a compound leading to the discovery of
new antibacterial drugs with minimum adverse effects. We observed that piperine and piperlongumine
are capable of improving the effectiveness of rifampicin and tetracycline. We suggest, therefore, that
dosages of combinations of these bioactive compounds with antibiotics could be a better option for the
treatment of bacterial infections than the conventional antibiotics which often show problems with
multidrug-resistant pathogens. Our study demonstrates that a combination of antibacterial (rifampicin
and tetracycline) with piperamide compounds (piperine and piperlongumine) could lead to minimal
systemic toxicity to normal cells during antimicrobial treatments.
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3.2. Antibacterial Synergistic Effects of Piperine and Piperlongumine against P. aeruginosa
Preliminary agar diffusion assays performed individually with piperamides and antibiotics
against P. aeruginosa (Table 1) showed that the inhibition zone diameters of tetracycline, rifampicin,
piperine, and piperlongumine were 34.6 mm, 30.3 mm, 14.4 mm, and 11.5 mm, respectively. When
the MIC of the various combinations was determined, the FIC index calculations showed mainly
antagonistic interactions between the piperamides and the antibiotics against P. aeruginosa, with
the exception of the 9:1 ratio of the piperine/rifampicin combination, which showed synergistic
activity (Table 3). P. aeruginosa is a Gram-negative pathogenic bacterium that causes systemic
infections in immunocompromised individuals and is often associated with antibacterial resistance [31].
For piperlongumine, no synergistic effect was observed in any of the antibiotic combinations (rifampicin
and tetracycline) against P. aeruginosa, although additive and antagonistic interactions were observed.
The results of tetracycline/piperlongumine and rifampicin/ piperlongumine combinations tested at
various ratios demonstrated no synergistic effects between tetracycline and piperlongumine as well
as between rifampicin and piperlongumine against P. aeruginosa. These results suggest that piperine
and piperlongumine may not improve the effectiveness of tetracycline against P. aeruginosa infections.
Indeed, appropriate measures should be taken to avoid too heavy a consumption of herbal drugs or
foods rich in piperine and piperlongumine when undergoing antimicrobial treatment with tetracycline
against diseases caused by P. aeruginosa.
For piperine, a synergistic interaction with rifampicin was observed for a rifampicin/piperine
combination at a ratio of 9:1 against P. aeruginosa, while antagonistic or additive interactions were
observed for the other combinations tested. Piperine was previously tested for its immunomodulatory
activity in enhancing the efficacy of rifampicin in a murine model of M. tuberculosis infection, thereby
acting in synergy with rifampicin to improve its therapeutic efficacy [32]. However, the synergistic
efficacy recorded in our study for a rifampicin/piperine combination showed that the efficacy could be
influenced by the ratio of the combination, i.e, the synergistic, additive, or antagonistic interactions
were greatly dependent on the ratio between rifampicin and piperine.
3.3. Antifungal Synergistic Effects of Piperine and Piperlongumine against C. albicans
When preliminary agar diffusion assays were performed singly on the piperamides and
itraconazole against C. albicans, the inhibition zone diameters of piperine, piperlongumine, and
itraconazole were 16.5 mm, 18.2 mm, and 15.2 mm, respectively (Table 1). The results of the FIC
index evaluations of the various combinations showed additive or antagonistic interactions (Table 3).
No synergistic effects were recorded in our study against C. albicans. C. albicans is an opportunistic
pathogen that is responsible for most yeast infections in humans [33]. These results demonstrate
that piperine and piperlongumine cannot improve the effectiveness of itraconazole, and thus herbal
formulations made from these bioactive compounds should be avoided while undergoing treatments
for yeast infections.
4. Materials and Methods
4.1. Sources of Antibiotics and Commercial Compounds
Analytical-grade commercial piperlongumine (≥ 97.0% purity) and piperine (≥ 97.0% purity) were
purchased from TCI Europe N.V. (Zwijndrecht, Belgium). Tetracycline hydrochloride (Sigma-Aldrich,
St. Louis MO, USA), rifampicin (Sigma-Aldrich), and itraconazole (Sigma-Aldrich) were the antibiotics
used in the investigation. The selection of tetracycline, rifampicin, and itraconazole was based on their
activity against bacterial and fungal strains in a previous study [34]. S. aureus American Type Culture
Collection ATCC 25923, P. aeruginosa ATCC 27853, and C. albicans ATCC 10231 cultures used in this
investigation were obtained from the Division of Pharmaceutical Biosciences, Faculty of Pharmacy,
University of Helsinki, Finland. The bacterial strains were selected because they are significant human
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pathogens capable of causing life-threatening nosocomial infections [35,36], while C. albicans, on the
other hand, causes fungal diseases in humans [37].
4.2. Preparation of Piperine, Piperlongumine, and Antimicrobials
Each of the commercial piperamides (piperine and piperlongumine) was prepared to a final
concentration of 5 mg/mL (stock solution) in 70% ethanol and tested in the initial screening. An initial
stock solution of 5 mg/mL was prepared for each of the antibiotics (tetracycline, rifampicin, and
itraconazole). Piperine and piperlongumine were also prepared in combination with tetracycline,
rifampicin, or itraconazole at various ratios according to the method of Van Vuuren et al. [10].
The combinations/dilutions were prepared at nine different ratios of 1:9, 2:8, 3:7, 4:6, 5:5, 6:4, 7:3,
8:2, 9:1 as follows: rifampicin/piperlongumine, rifampicin/piperine, tetracycline/piperlongumine,
tetracycline/piperine, itraconazole/piperine, and itraconazole/piperlongumine.
4.3. Agar Disk-Diffusion Method
The agar disk-diffusion method was applied for the initial screening of the nine combination
ratios according to the method of the Clinical and Laboratory Standards Institute [38]. Sterile Petri
dishes (∅ = 14 cm, VWR International Oy, Helsinki, Finland) were used for the screening. For the
antibacterial screening against S. aureus and P. aeruginosa, 25 mL of sterile base agar (Antibiotic agar
No. 2, Difco, VWR) was applied as a bottom layer into the sterile Petri dishes, using a sterile serological
pipet (Falcon; BDLabware Europe) and allowed to solidify. Thereafter, 25 mL of isosensitest agar
(OXOID, ThermoFisher Scientific, Waltham, MA, USA) was applied as the top layer. For the antifungal
screening, 25 mL of sterile base agar (Antibiotic agar No. 2, Difco VWR) was applied as a bottom layer
into the sterile Petri dishes and 25 mL of Saboraud agar (OXOID, ThermoFisher Scientific, Basingstoke,
United Kingdom) was applied as the top layer. The agar in the Petri dishes was allowed to solidify
and then stored at +4 ◦C. The screening was initiated with the inoculation of the bacterial strains or
C. albicans onto solid nutrient or Saboraud agar slants that were incubated overnight for the bacterial
strains and 48 h for the fungus at +37 ◦C. Viable bacterial and fungal cultures from the agar slants
were used to prepare an inoculum for the test. Bacterial and fungal specimens from the agar slants
were transferred into 2 mL of a 0.9% (w/v) sodium chloride (NaCl) solution in a sterile glass tube,
using a sterile inoculation loop. In all, 1 mL of the suspension was transferred into another sterile
glass tube, and the absorbance was measured at 625 nm (UV–Visible Spectrophotometer, Pharmacia
LKB-Biochrom 4060; Pfizer Inc., New York, NY, USA). The other milliliter of the suspension (sterile part)
was diluted with the 0.9% NaCl solution so that the absorbance at 625 nm became 0.1 (this suspension
contained approximately 1.5 × 108 colony-forming units (CFUs)/mL). In all, 200 µL of this diluted
bacterial or fungal suspension were spread evenly on each Petri dish and left to dry for several seconds
with the lid open. A sterile cork borer (11 mm diameter) was used to make six equidistant holes on
the agar surface of the Petri dishes. A total of 200 µL of the 5 mg/mL concentration of each of the
piperamides and 200 µL of the 10 mg/mL antimicrobial were carefully pipetted into the holes; 70%
ethanol was used as the solvent control. The first screening of the combined samples was done in
the same manner as described above for the agar diffusion method, and the various inhibition zones
were recorded. The Petri dishes were transferred to the cold room and incubated at +4 ◦C for 1 h.
Thereafter, they were incubated at +37 ◦C, overnight for the bacterial strains and 48 h for the fungal
strain. The diameters of the zones of inhibition were measured with a caliper under a Petri dish
magnifier and expressed as the mean of the diameters of three replicates ± the standard error of the
mean (SEM).
4.4. Microdilution Method for Minimum Inhibitory Concentration Estimation
The MIC was estimated for the five best combinations of each piperamide/antimicrobial. The MIC
was taken as the lowest concentration of the piperamide/antimicrobial resulting in the inhibition of
at least 90% of the growth of the bacterial or fungal strain. The MIC values were determined using
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a microdilution turbidimetric broth method based on the guidelines of the Clinical and Laboratory
Standards Institute [38]. For MIC evaluation, two-fold serial dilutions from 2500 to 9.75 µg/mL
were prepared in sterile Mueller–Hinton broth (bacterial strains) and Saboraud broth (C. albicans) for
each of the piperamide/antimicrobial combinations. The commercially pure compounds, piperine
and piperlongumine (5 mg/mL concentrations in 70% ethanol), were two-fold serially diluted in
Mueller–Hinton broth for the bacterial strains and Saboraud broth for the fungal strain. Tetracycline,
rifampicin, and itraconazole were similarly diluted in Mueller–Hinton broth or Saboraud broth from
125 to 0.48 µg/mL, respectively; 96-well microtiter plates (Nunc, Nunclone; Nalge Nunc International,
Roskilde, Denmark) were used for the tests. The bacterial or fungal cultures were inoculated in
5 mL of Mueller–Hinton broth and grown for 24 h at +37 ◦C for the bacterial strains or in 5 mL
of Saboraud broth and grown for 48 h at +37 ◦C for C. albicans before the test. Absorbance of
1 mL of the overnight bacterial culture was measured for turbidity at 625 nm, using a UV–Visible
Spectrophotometer type 1510 (ThermoFisher Scientific). The absorbance was adjusted to 0.1 at 625 nm
(approximately 1.0 × 108 CFUs/mL). A total of 100 µL of this suspension A625 = 0.1 was further
diluted a hundredfold to obtain a working suspension or inoculum containing 1.0 × 106 CFUs/mL.
In all, 100 µL of this inoculum and 100 µL of each of thepiperamide/antimicrobial combinations and
solvent controls were introduced into the 96-well microtiter plates. Each well therefore contained
5 × 105 CFUs/mL. The growth control (GC) wells contained only the bacterial suspension, and the
test (T) wells contained the piperamide/antimicrobial + bacterial suspension. Moreover, negative
control wells were prepared for each piperamide/antimicrobial combination ratio tested, and these
wells contained the piperamide/antimicrobial combinations at different ratios and the broth only.
The microwell plates were incubated for 24 h in an incubator coupled to a shaker at +37 ◦C. The turbidity
of the wells at 620 nm was recorded using a Victor 1420 spectrophotometer (PerkinElmer (Wallac Oy),
Turku, Finland). The tests were done in triplicate, and the percentage growth was expressed as the
mean of these triplicates ± the SEM.
4.5. Fractional Inhibitory Concentration Index
The FIC index was used to estimate the synergy [5,26]. For the FIC index calculation, the MIC
values of five combinations of each piperamide/antimicrobial at different ratios were used to calculate
FIC (A) and FIC (B), using the equation below:
The FIC values were calculated as follows:
FIC(A) = MICvalueo f combinedpiperamideandantimicrobialMICvalueo f antimicrobialalone
FIC(B) = MICvalueo f combinedpiperamideandantimicrobialMICvalueo f piperamidealone
FICindex = FIC(A) + FIC(B)
A FIC index value ≤ 0.5 was interpreted as synergy. The FIC index was calculated on the basis of
the above-mentioned equation, in which the FIC index = X + Y and the interactions are defined as:
FIC index ≤ 0.5, synergy; > 0.5 to ≤ 1.0, additive; > 1.0 to ≤ 2.0, indifferent; and > 2.0, antagonistic [26].
5. Conclusions
Piperine and piperlongumine are possible antibiotic adjuvants that should be applied in drug
discovery for use as effective antibacterial treatments. The synergistic efficacy of piperlongumine and
piperine in combination with rifampicin has shown that these two piperamides are bioactive scaffolds
that could aid in fighting against multidrug-resistant pathogens, thereby improving the effectiveness
of rifampicin in the treatment of infectious diseases. Our results show that the synergistic efficacy
of piperamide compounds is dependent on the concentration and ratio of the combination. This
indicates that the use of piperine and piperlongumine may minimize the adverse effects associated with
conventional tetracycline and rifampicin and improve the effectiveness of these antibiotics. However,
the antagonistic effects observed with the commercial compounds/antibiotics used against P. aeruginosa
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in this study demonstrate that appropriate caution should be taken to avoid the consumption of herbal
drugs made from Piper species during antibacterial treatment therapies against P. aeruginosa infections.
We suggest that piperine and piperlongumine could be considered as therapeutic bioactive compounds
for antibacterial drug discovery. Further studies should be conducted on the mode of activity of the
synergistic interaction between piperamides and antibiotics.
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